Zobrazeno 1 - 10 of 160 pro vyhledávání: '"Fugazza, E"'
1
Akademický článek
Udienza 14 gennaio 1929; Pres. ed est. Carrara, P. M. Gatti (concl. diff.) — Ricc. Fugazza e Salerio (Avv. Gonzales Mattiello)
Publikováno v: Il Foro Italiano, 1929 Jan 01. 54, 147/148-149/150.
Externí odkaz: https://www.jstor.org/stable/23126072
Zobrazit plný text záznamu
3
Abnormal expression patterns of WT1-as, MEG3 and ANRIL long non-coding RNAs in CD34+ cells from patients with primary myelofibrosis and their clinical correlations
Autor: Pennucci, V, Zini, R, Norfo, R, Guglielmelli, P, Bianchi, E, Salati, S, Sacchi, G, Prudente, Z, Tenedini, E, Ruberti, S, Paoli, C, Fanelli, T, Mannarelli, C, Tagliafico, E, Ferrari, S, Vannucchi, Am, Manfredini, R, on behalf of Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators Collaborators Vannucchi AM, Balliu, M, Bartalucci, N, Bogani, C, Bosi, A, Fjerza, R, Martinelli, S, Pancrazzi, A, Pieri, L, Bisognin, Andrea, Bortoluzzi, Stefania, Coppe, Alessandro, Saccoman, Claudia, Masciulli, A, Giovani, B, Azzan, C, Badalucco, S, Balduini, A, Bonetti, E, Campanelli, R, Catarsi, P, Isgrò, Ma, Lupo, Ml, Magrini, U, Massa, M, Poletto, V, Rosti, V, Villani, L, Cazzola, M, Ambaglio, I, Bernasconi, P, Casetti, Ic, Catricalà, S, Elena, C, Fugazza, E, Gallì, A, Malcovati, L, Milanesi, C, Pascutto, C, Pietra, D, Ripamonti, F, Rossi, M, Rumi, E, Dejana, E, Breviario, F, Corada, M, Erba, Bg, Rambaldi, A, Barbui, T, Ferrari, Ml, Finazzi, G, Finazzi, Mc, Gritti, G, Belotti, C, Boroni, C, Salmoiraghi, S, Amaru, A, Golay, J, Cilloni, D, Campia, V, Carturan, S, Guerrasio, A, Montanari, M, Zini, R.
Long non-coding RNAs (lncRNAs), an emerging group of gene expression regulators in normal and cancer cells, are defined as endogenous RNAs consisting of more than 200 nucleotides and lacking an ope...
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01e32bcbe88b1bad6daf18f6012e5b49
https://hdl.handle.net/11380/1060249
Zobrazit plný text záznamu
4
Akademický článek
Smoldering multiple myeloma: the role of different scoring systems in identifying high-risk patients in real-life practice.
Autor: Cocito F; Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy., Mangiacavalli S; Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy., Ferretti VV; Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.; University of Pavia, Pavia, Italy., Cartia CS; Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy., Ganzetti M; Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.; University of Pavia, Pavia, Italy., Benveuti P; Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.; University of Pavia, Pavia, Italy., Pompa A; Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore di Milano Policlinico, Milano, Italy., Catalano M; University of Pavia, Pavia, Italy., Fugazza E; Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy., Landini B; Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy., Arcaini L; Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.; University of Pavia, Pavia, Italy., Corso A; Ospedale Nuovo di Legnano, Division of Hematology, Legnano, Italy.
Publikováno v: Leukemia & lymphoma [Leuk Lymphoma] 2019 Dec; Vol. 60 (12), pp. 2968-2974. Date of Electronic Publication: 2019 Jun 06.
Zobrazit plný text záznamu
5
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis
Autor: Rumi, E, Pietra, D, Pascutto, C, Guglielmelli, P, Martínez Trillos, A, Casetti, I, Colomer, D, Pieri, L, Pratcorona, M, Rotunno, G, Sant'Antonio, E, Bellini, M, Cavalloni, C, Mannarelli, C, Milanesi, C, Boveri, E, Ferretti, V, Astori, C, Rosti, V, Cervantes, F, Barosi, G, Vannucchi, Am, Cazzola, M, Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators Collaborators Vannucchi AM, Balliu, M, Bartalucci, N, Biamonte, F, Bisognin, A, Bogani, C, Bortoluzzi, S, Bosi, A, Coppe, A, Fanelli, T, Fjerza, R, Loiacono, I, Marchioli, R, Martinelli, S, Masciulli, A, Pancrazzi, A, Paoli, C, Saccoman, C, Spolverini, A, Susini, Mc, Tozzi, L, Azzan, C, Badalucco, S, Balduini, A, Bonetti, E, Campanelli, R, Catarsi, P, Isgrò, Am, Lupo, Ml, Magrini, U, Massa, M, Poletto, V, Villani, L, Ambaglio, I, Bernasconi, P, Casetti, Ic, Catricalà, S, Elena, C, Fugazza, E, Gall, A, Malcovati, L, Ripamonti, F, Rossi, M, Dejana, E, Breviario, F, Corada, M, Erba, Bg, Rambaldi, A, Amaru, A, Barbui, T, Belotti, C, Boroni, C, Ferrari, Ml, Finazzi, G, Finazzi, Mc, Golay, J, Gritti, G, Salmoiraghi, S, Cilloni, Daniela, Campia, V, Carturan, S, Guerrasio, Angelo, Manfredini, R, Bianchi, E, Salati, S, Tagliafico, E, Tenedini, E, Zini, R.
We studied the impact of driver mutations of JAK2, CALR, (calreticulin gene) or MPL on clinical course, leukemic transformation, and survival of patients with primary myelofibrosis (PMF). Of the 617 subjects studied, 399 (64.7%) carried JAK2 (V617F),
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fcc20185ca75ffed69c01238001098b
https://europepmc.org/articles/PMC4133481/
Zobrazit plný text záznamu
6
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
7
Tie2 Expressing Monocytes in the Spleen of Patients with Primary Myelofibrosis
Autor: Campanelli, R., Fois, G., Catarsi, P., Poletto, V., Villani, L., Erba, B. G., Maddaluno, L., Jemos, B., Salmoiraghi, S., Guglielmelli, P., Abbonante, V., Di Buduo, C. A., Balduini, A., Iurlo, A., Barosi, G., Rosti, V., Massa, M., Vannucchi, A. M., Balliu, M., Bartalucci, N., Bogani, C., Bosi, A., Calabresi, L., Corbizzi Fattori, G., Fanelli, T., Fjerza, R., Gesullo, F., Mannarelli, C., Merli, L., Pacilli, A., Pancrazzi, A., Paoli, C., Pieri, L., Rotunno, G., Sant'Antonio, E., Bonetti, E., Cazzola, M., Ambaglio, I., Bernasconi, P., Casetti, C. I., Catricala, S., Elena, C., Fugazza, E., Galli, A., Malcovati, L., Milanesi, C., Pascutto, C., Pietra, D., Ripamonti, F., Rossi, M., Rumi, E., Dejana, E., Breviario, F., Corada, M., Malinverno, M., Rambaldi, A., Chioda, G., Ferrari, M. L., Finazzi, G., Finazzi, M. C., Belotti, C., Boroni, C., Amaru, A., Golay, J., Bortoluzzi, S., Bisognin, A., Coppe, A., Saccoman, C., Manfredini, R., Artuso, L., Bernardis, I., Bianchi, E., Montanari, M., Pennucci, V., Prudente, Z., Rontauroli, S., Rossi, C., Ruberti, S., Salati, S., Tagliafico, E., Tenedini, E., Zini, R.
Publikováno v: PLoS ONE, Vol 11, Iss 6, p e0156990 (2016)
PLoS ONE
Primary myelofibrosis (PMF) is a Philadelphia-negative (Ph-) myeloproliferative disorder, showing abnormal CD34+ progenitor cell trafficking, splenomegaly, marrow fibrosis leading to extensive extramedullary haematopoiesis, and abnormal neoangiogenes
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed4d9b3ebfde475b7177a80862ee66d6
https://doi.org/10.1371/journal.pone.0156990
Zobrazit plný text záznamu
8
Akademický článek
Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria.
Autor: Rumi E; Department of Molecular Medicine, University of Pavia, Pavia, Italy.; Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy., Boveri E; Anatomic Pathology Section, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy., Bellini M; Department of Molecular Medicine, University of Pavia, Pavia, Italy., Pietra D; Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy., Ferretti VV; Department of Molecular Medicine, University of Pavia, Pavia, Italy., Sant'Antonio E; Department of Oncology, Division of Hematology, Ospedale San Luca, Lucca, Italy., Cavalloni C; Department of Molecular Medicine, University of Pavia, Pavia, Italy.; Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy., Casetti IC; Department of Molecular Medicine, University of Pavia, Pavia, Italy., Roncoroni E; Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy., Ciboddo M; Department of Molecular Medicine, University of Pavia, Pavia, Italy., Benvenuti P; Department of Molecular Medicine, University of Pavia, Pavia, Italy., Landini B; Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy., Fugazza E; Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy., Troletti D; Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy., Astori C; Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy., Cazzola M; Department of Molecular Medicine, University of Pavia, Pavia, Italy.; Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy.
Publikováno v: Oncotarget [Oncotarget] 2017 Oct 06; Vol. 8 (60), pp. 101735-101744. Date of Electronic Publication: 2017 Oct 06 (Print Publication: 2017).
Zobrazit plný text záznamu
9
Akademický článek
Sequential evaluation of CALR mutant burden in patients with myeloproliferative neoplasms.
Autor: Cavalloni C; Department of Molecular Medicine, University of Pavia, Pavia, Italy., Rumi E; Department of Molecular Medicine, University of Pavia, Pavia, Italy.; Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy., Ferretti VV; Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy., Pietra D; Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy., Roncoroni E; Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy., Bellini M; Department of Molecular Medicine, University of Pavia, Pavia, Italy., Ciboddo M; Department of Molecular Medicine, University of Pavia, Pavia, Italy., Casetti IC; Department of Molecular Medicine, University of Pavia, Pavia, Italy., Landini B; Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy., Fugazza E; Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy., Troletti D; Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy., Astori C; Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy., Cazzola M; Department of Molecular Medicine, University of Pavia, Pavia, Italy.; Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy.
Publikováno v: Oncotarget [Oncotarget] 2017 May 16; Vol. 8 (20), pp. 33416-33421.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje